Veroscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VeroScience, founded in 2003 and based in Raleigh, NC, is a private biotech leveraging circadian neuroendocrine science to develop novel therapeutics. The company's core platform, Circadian Neuroendocrine Resetting Therapy (CNRT), underpins its approved product for type 2 diabetes (Cycloset) and a pipeline exploring applications in pediatric diabetes and oncology. Operating as a small, efficient organization, VeroScience advances its programs through nationwide preclinical/clinical research and strategic academic and industry collaborations.

Metabolic DiseasesImmunological DisordersOncology

Technology Platform

Circadian Neuroendocrine Resetting Therapy (CNRT) platform targeting dopamine D2 receptors to reset dysfunctional circadian rhythms impacting metabolism and immunity. Secondary Photo Immuno-Resetting Therapy (PIRT) platform for site-specific cancer photodynamic therapy.

Opportunities

Significant opportunity exists in expanding the label of its approved drug, Cycloset, into the underserved pediatric type 2 diabetes market.

Furthermore, successfully applying its circadian platform to immuno-oncology and immunological disorders could open up massive new markets and position the company as a pioneer in the growing field of chronotherapy.

Risk Factors

Key risks include clinical failure of pipeline programs, particularly in challenging indications like pancreatic cancer, and commercial competition for its approved product in the crowded diabetes market.

As a small private company, it also faces funding and resource constraints for advancing development.

Competitive Landscape

In diabetes, Cycloset competes with numerous established and novel drug classes from large pharmaceutical companies. In its pipeline oncology and immunology programs, it faces competition from both large biopharma and other biotechs exploring circadian biology and novel targeted therapies, though its specific mechanistic approach provides differentiation.

More companies in Drug Delivery & Formulation →More companies in United States →